Back

Scholar Rock shares jump 11.9% after FDA approves ISEMBYLD for SMA

Verifying
  • Scholar Rock announced FDA approval of ISEMBYLD for children and adults with SMA.
  • 11.9%: Scholar Rock shares reached $62.00 in pre-market trading.
  • Scinai led gainers, while Picocela led decliners in the pre-market list.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Scholar Rock shares jump 11.9% after FDA approves ISEMBYLD for SMA - CoinPost Terminal